Pfizer presents efficacy data of Prevenar 13 at conference

NEW YORK A phase-3 clinical trial found that a pneumococcal disease vaccine was well-tolerated and immunogenic in young, healthy children.

Pfizer said that children up to 5 years of age showed increased immune response to its Prevenar 13 vaccine when the children received three previous doses of Prevenar. The data were presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases in Tel Aviv, Israel.

Prevenar 13 includes the seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) in Prevenar plus six additional serotypes (1, 3, 5, 6A, 7F, and 19A). Together, these 13 serotypes represent the most prevalent invasive disease-causing strains in young children worldwide, Pfizer said. Prevenar 13 is indicated for the prevention of invasive disease, pneumonia, and otitis media in infants and children from 6 weeks to 5 years of age.

“These data further suggest the importance of providing direct coverage against the 13 most common pneumococcal disease-causing serotypes worldwide,” said Emilio Emini, Ph.D., chief scientific officer for vaccine research at Pfizer.